Welcome to our dedicated page for Angle Plc news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on Angle Plc stock.
ANGLE PLC S/ADR (ANPCY) is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology. The company's proprietary Parsortix system efficiently harvests CTCs from blood samples, enabling downstream molecular analysis for comprehensive biomarker assessment. ANGLE's cutting-edge technologies, such as the Portrait+ CTC Staining Kit, enable the identification and analysis of diverse CTC phenotypes and clusters, providing valuable insights into cancer progression, metastasis, and treatment response. With a focus on diagnostic products and clinical services, ANGLE continues to drive advancements in precision medicine through its state-of-the-art liquid biopsy solutions.
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces a breakthrough publication by researchers at the University of New Mexico, US, regarding the use of Parsortix system in pre-clinical model for gene expression profiling associated with melanoma brain metastasis. The study reveals the system's pivotal role in prescribing more targeted treatments based on patient needs, with a positive impact on therapeutic regime effectiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) launches Portrait+ CTC staining kit, combining Parsortix technology with an immunofluorescent assay for precise CTC identification, characterisation, and enumeration. The test is designed for accurate, repeatable results and can be used in breast, lung, prostate, and ovarian cancers. EMT transition step in cancer cells is also detected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.87%
Tags
-
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) expects a 120% increase in revenue for 2023 to c. £2.2 million, with sales secured in 2023 expected to be c. £3.3 million. Revenue for 2024 is expected to triple compared to 2023. The cash runway has been extended into Q2 2025. The streamlining of the Services business is expected to result in cost savings of c. £3 million per annum in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces the launch of its Portrait PD-L1 test, a minimally invasive liquid biopsy using CTCs from the Parsortix system to determine PD-L1 status in cancer patients. The test aims to provide accurate, repeatable, and precise results for CTC PD-L1 biomarker expression, allowing real-time assessment of the biomarker status, which may address the fundamental flaw in current PD-L1 tests via a simple blood test. The global PD-1 and PD-L1 immunotherapy market is currently valued at US $36.9 billion per annum, and analysts predict the market to reach US $109.1 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc announces the publication of a study using the Parsortix system that sheds new light on the characteristics of circulating tumor cells (CTCs) in Head and Neck Squamous Cell Carcinoma (HNSCC). The study demonstrates the feasibility of using mass cytometry for the comprehensive characterization of CTCs captured by the Parsortix system, providing a deep understanding of their phenotypic status and diversity. The findings offer the potential for the development of more precise and personalized treatment strategies for HNSCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
Rhea-AI Summary
ANGLE plc showcased the Parsortix system at the Advances in Circulating Tumor Cells conference, receiving positive feedback. Key highlights include predictive CTC biomarkers for treatment resistance in NSCLC, clinical significance of mesenchymal CTCs, and dual analysis of CTCs and ctDNA. ANGLE plans to expand translational research use and grow biopharma services business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc announces interim results for the period ended 30 June 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
-
Rhea-AI Summary
ANGLE plc announces launch of Portrait Flex assay
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Angle Plc (ANPCY)?
The current stock price of Angle Plc (ANPCY) is $1.8465 as of February 7, 2025.
What is the market cap of Angle Plc (ANPCY)?
The market cap of Angle Plc (ANPCY) is approximately 62.9M.
What is ANGLE PLC S/ADR known for?
ANGLE is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology.
What technologies does ANGLE use for CTC analysis?
ANGLE utilizes the Parsortix system for efficient harvesting of CTCs from blood samples, enabling downstream molecular analysis for comprehensive biomarker assessment.
How does ANGLE's Portrait+ CTC Staining Kit benefit cancer research?
The Portrait+ CTC Staining Kit enables the identification and analysis of diverse CTC phenotypes and clusters, providing valuable insights into cancer progression, metastasis, and treatment response.
What is the focus of ANGLE's commercial businesses?
ANGLE's commercial focus is on diagnostic products and clinical services, offering advanced liquid biopsy solutions and custom assay development for pharma.
Angle Plc